Novartis | Des Atouts



Assets Changement Date
AbbVie USD 135.16B 8.26B 2024-12
Alcon AG USD 30.35B 15M 2024-12
Almirall EUR 2.4B 75.28M 2024-12
Amgen USD 89.37B 2.47B 2025-03
AstraZeneca USD 106.25B 2.22B 2025-03
Autolus Therapeutics Ltd 746.34M 36.39M 2025-03
Bayer EUR 110.85B 3.9B 2024-12
Biogen USD 28.03B 16.2M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Eli Lilly USD 89.39B 10.67B 2025-03
Fresenius EUR 43.21B 343M 2025-03
Fresenius Medical Care EUR 32.74B 832M 2025-03
Galapagos EUR 4.02B 113.77M 2025-03
Genmab DKK 6.59B 39.22B 2025-03
Gilead Sciences USD 56.43B 2.56B 2025-03
GlaxoSmithKline GBP 60.71B 1.24B 2025-03
GRIFOLS EUR 21.41B 1.12B 2024-12
Hikma Pharmaceutical USD 4.85B 167M 2024-06
J&J USD 193.67B 13.57B 2025-03
Lonza CHF 19.73B 1.85B 2024-12
Merck EUR 51.57B 1.42B 2024-12
Merck USD 115.12B 1.98B 2025-03
Novartis USD 102.25B 1.28B 2024-12
Novartis USD 102.25B 1.28B 2024-12
Novo Nordisk 489.16B 91.72B 2025-03
Orion EUR 1.7B 72.7M 2025-03
Pfizer USD 208.03B 5.37B 2025-03
Philips EUR 27.17B 1.81B 2025-03
Recordati EUR 5.17B 962.56M 2025-03
Regeneron Pharmaceuticals USD 37.55B 214.2M 2025-03
Roche Holding CHF 101.8B 6.02B 2024-12
Sanofi 131.89B 906M 2025-03
UCB EUR 17.35B 1.72B 2024-12



Novartis Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.